GlassScriptPhysician profile
Tiffany Nagy
NPI 1083351654
$4,099.28
in general payments reported to CMS, 2019-2025
39 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $937 · 2024: $2,092 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,999 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,999.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $598.80 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Daiichi Sankyo INC. | $577.57 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Merck Sharp & Dohme LLC | $481.12 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $297.56 | 2023-2025 | Lynparza, Enhertu, Calquence |
| Lilly USA, LLC | $247.71 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $214.96 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Pharmaessentia USA Corporation | $165.13 | 2023-2025 | Besremi |
| Eisai INC. | $118.91 | 2023-2025 | |
| Incyte Corporation | $114.97 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Emd Serono, INC. | $113.00 | 2023-2025 | Bavencio, Tepmetko |
| Novartis Pharmaceuticals Corporation | $111.75 | 2024-2025 | |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.16 | 2023-2025 | |
| Pfizer INC. | $72.36 | 2024-2025 | |
| Genmab U.S., INC. | $69.90 | 2023-2025 | Epkinly, Tivdak |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $55.29 | 2025 | Pyrukynd |
| Davol INC. | $52.03 | 2025 | Arista |
| Tersera Therapeutics LLC | $51.00 | 2023-2024 | Zoladex |
| Alexion Pharmaceuticals, INC. | $48.80 | 2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $46.27 | 2023-2025 | Libtayo |
| Caris Mpi, INC. | $45.69 | 2025 | Mi Cancer Seek |
| Verastem, INC. | $41.95 | 2025 | Avmapki Fakzynja Co-Pack |
| Acera Surgical, INC. | $36.86 | 2023 | Restrata Wound Matrix |
| Takeda Pharmaceuticals U.S.A., INC. | $34.51 | 2024 | Fruzaqla, Ninlaro |
| Stemline Therapeutics INC. | $33.82 | 2024-2025 | Elzonris, Orserdu |
| Taiho Oncology, INC. | $31.75 | 2024 | |
| Genentech USA, INC. | $31.06 | 2023-2024 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Hologic Sales and Service, LLC | $24.58 | 2025 | Acessa Provu System |
| Myriad Genetic Laboratories, INC. | $20.62 | 2024 | Myrisk |
| Tempus Ai, INC | $20.15 | 2024 | Xt Cdx |
| Deciphera Pharmaceuticals INC. | $18.72 | 2024 | Tgct, Qinlock |
| Blueprint Medicines Corporation | $17.35 | 2023 | Ayvakit |
| Servier Pharmaceuticals LLC | $17.00 | 2024 | |
| Edwards Lifesciences Corporation | $16.89 | 2025 | Sapien 3 Ultra Resilia |
| Genzyme Corporation | $16.73 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $16.59 | 2024 | Sancuso |
| Abbvie INC. | $16.19 | 2023 | |
| Seagen INC. | $15.71 | 2023 | Padcev |
| Amgen INC. | $13.83 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Nagy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.